

— —

CONSOLIDATED STATEMENT OF PROFIT OR LOSS

For the year ended 31 December 2023

	N	2023 RMB'000	RMB'000
REVENUE	3	41,248,505	41,248,505
Cost of sales		(21,595,309)	(21,595,309)
Gross profit		19,653,196	19,653,196
Other income	4	524,980	524,980
Depreciation and amortization		(9,712,237)	(9,712,237)
Impairment loss on financial assets		(4,495,128)	(4,495,128)
Impairment loss on non-current assets		(131,927)	(131,927)
Impairment loss on equity investments		(4,346,045)	(4,346,045)
Other income	6	1,392,007	1,392,007
Other expenses		(831,601)	(831,601)
Other income		363,645	363,645
Other expenses	7	(1,324,831)	(1,324,831)
Other income		(202,030)	(202,030)
Other expenses		2,386,879	2,386,879
PROFIT BEFORE TAX	5	3,276,908	3,276,908
Income tax expense	8	(369,504)	(369,504)
PROFIT FOR THE YEAR		<u>2,907,404</u>	<u>2,907,404</u>
Other income		2,398,606	2,398,606
Other expenses		508,798	508,798
Other income		<u>2,907,404</u>	<u>2,907,404</u>
Other income	10	RMB0.90	RMB0.90
Other income		<u>RMB0.90</u>	<u>RMB0.90</u>

31 D ~~Re~~ r 2023

PROFIT FOR THE YEAR

2,907,404

$\frac{1}{\sqrt{n}} \sum_{i=1}^n \left(\frac{\partial}{\partial \theta} \log f(X_i; \theta) \right)$

[illegible]

	2023 RMB'000	2022 RMB'000
NON-CURRENT LIABILITIES		
Long-term bank borrowings	13,504,923	13,504,923
Long-term payables	2,049,589	2,049,589
Long-term deferred income	3,445,191	3,445,191
Long-term prepayments	319,785	319,785
Long-term deposits	639,399	639,399
Long-term other payables	3,136,874	3,136,874
	<u>23,095,761</u>	<u>23,095,761</u>
	<u>56,577,885</u>	<u>56,577,885</u>
EQUITY		
Equity attributable to owners of the parent		
Capital	2,672,399	2,672,399
Reserves	(41,928)	(41,928)
	<u>43,015,915</u>	<u>43,015,915</u>
	<u>45,646,386</u>	<u>45,646,386</u>
Non-controlling interests	<u>10,931,499</u>	<u>10,931,499</u>
	<u>56,577,885</u>	<u>56,577,885</u>

1.1 BASIS OF PREPARATION

“HKFRSs” / “HKASs” / “HKICPA” / “RMB”

Basis of consolidation

“Group”

[illegible][illegible]
$$- \frac{1}{\sqrt{\pi}} \int_0^x \frac{f(t)}{(x-t)^{1/2}} dt = - \frac{1}{\sqrt{\pi}} \left[f(x) \int_0^x \frac{dt}{(x-t)^{1/2}} + \int_0^x \frac{f'(t)(x-t)^{1/2} dt}{1} \right]$$
[illegible][illegible][illegible][illegible]

1.2 CHANGES IN ACCOUNTING POLICIES AND DISCLOSURES

$$I \quad r \quad K \quad C \quad r \quad K$$

$$D \quad K \quad r \quad A \quad K \quad K \quad P \quad K$$

$$D \quad A \quad K \quad K \quad E \quad \mathcal{H}$$

$$D \quad rr \quad T \quad r \quad A \quad L \quad r \quad \mathcal{H} \quad S \quad Tr \quad K$$

$$I \quad r \quad T \quad R \quad \mathcal{H} \quad - \quad P \quad r \quad T \quad M \quad R$$

1. The Company has adopted the Hong Kong Financial Reporting Standards ("HKFRS") issued by the Hong Kong Accounting Standards Board ("HKASB") for the financial year ended 31 March 2014. The HKFRS are the same as the International Financial Reporting Standards ("IFRS") issued by the International Accounting Standards Board ("IASB") for the financial year ended 31 March 2014, except for the differences in the application of the HKFRS and the IFRS in the areas of the recognition, measurement, presentation and disclosure of financial instruments, which are disclosed in the notes to the financial statements.

1.3 ISSUED BUT NOT YET EFFECTIVE HONG KONG FINANCIAL REPORTING STANDARDS

The Company has also adopted the HKFRS issued by the HKASB for the financial year ended 31 March 2014, which are the same as the IFRS issued by the IASB for the financial year ended 31 March 2014, except for the differences in the application of the HKFRS and the IFRS in the areas of the recognition, measurement, presentation and disclosure of financial instruments, which are disclosed in the notes to the financial statements.

Year ended 31 December 2023

	Pharma- ceutical manufacturing RMB'000	Medical devices and medical diagnosis RMB'000	Healthcare Service RMB'000	Pharma- ceutical distribution and retail RMB'000	Others RMB'000	Eliminations RMB'000	Total RMB'000
Pharmaceutical manufacturing	30,080,246	4,386,495	6,667,137	—	114,627	—	41,248,505
Medical devices and medical diagnosis	470,731	54,063	42,866	—	35,726	(603,386)	—
	<u>30,550,977</u>	<u>4,440,558</u>	<u>6,710,003</u>	<u>—</u>	<u>150,353</u>	<u>(603,386)</u>	<u>41,248,505</u>
Healthcare Service	2,133,620	(126,443)	(200,661)	—	(80,398)	(119,758)	1,606,360
Pharmaceutical distribution and retail	342,065	56,167	49,453	—	49,415	—	497,100
Others	329,170	56	23,039	—	149,667	—	501,932
Eliminations	235,169	30,611	24,260	—	2,615	(23,896)	268,759
	(254,032)	(34,398)	(245,598)	—	(44,186)	133,272	(444,942)
	(288,780)	(93,932)	(65,354)	—	(1,002)	1,173	(447,895)
	(209,238)	—	(1,376)	—	8,584	—	(202,030)
	27,365	128,527	1,427	2,242,195	(12,635)	—	2,386,879
							(889,255)
	2,315,339	(39,412)	(414,810)	2,242,195	72,060	(9,209)	3,276,908
	(341,571)	6,666	(25,005)	—	(6,189)	—	(366,099)
							(3,405)
	1,973,768	(32,746)	(439,815)	2,242,195	65,871	(9,209)	2,907,404
	60,228,777	10,328,867	15,575,622	18,972,525	5,096,173	(2,997,488)	107,204,476
	67,249	—	—	—	11,661	—	78,910
	505,797	1,483,895	688,591	18,972,525	2,151,305	—	23,802,113
							6,226,751
							113,431,227
	24,081,873	2,672,929	7,609,566	—	2,077,696	(13,666,779)	22,775,285
							34,078,057
							56,853,342
	2,186,643	369,461	532,164	—	114,485	—	3,202,753
	224,224	82,804	53,055	—	—	—	360,083
	4,470,575	551,519	602,539	—	133,195	—	(8,414)
							5,757,828

— —

=====

Revenue from contracts with customers

(i) Detailed description

For the year ended 31 December 2023

Segments	Pharmaceutical manufacturing RMB'000	Medical devices and medical diagnosis RMB'000	Healthcare Service RMB'000	Pharmaceutical distribution and retail RMB'000	Others RMB'000	Total RMB'000
Type of goods or services						
Pharmaceutical products	28,532,071	4,245,408	686,595	—	32,949	33,497,023
Medical devices and medical diagnosis	1,517,980	127,270	5,976,603	—	33,450	7,655,303
Healthcare services	22,320	11,258	—	—	—	33,578
	<u>30,072,371</u>	<u>4,383,936</u>	<u>6,663,198</u>	<u>—</u>	<u>66,399</u>	<u>41,185,904</u>
Geographical markets						
China	22,629,786	1,466,935	6,654,040	—	64,528	30,815,289
Overseas	7,442,585	2,917,001	9,158	—	1,871	10,370,615
	<u>30,072,371</u>	<u>4,383,936</u>	<u>6,663,198</u>	<u>—</u>	<u>66,399</u>	<u>41,185,904</u>
By product line						
Pharmaceutical products	28,554,391	4,256,666	686,595	—	32,949	33,530,601
Medical devices and medical diagnosis	1,205,727	34,162	5,976,603	—	33,450	7,249,942
Healthcare services	312,253	93,108	—	—	—	405,361
	<u>30,072,371</u>	<u>4,383,936</u>	<u>6,663,198</u>	<u>—</u>	<u>66,399</u>	<u>41,185,904</u>

(ii) $Pe \quad a \quad ce \quad b \quad a$

[illegible]

S.

[illegible]
$$R \quad r \quad r \quad K$$
[illegible][illegible][illegible]

2023
RMB'000

$$P_{\frac{1}{2}}(I) \otimes P_{\frac{1}{2}}(I) = P_{\frac{1}{2}}(I)$$

▼] i h i]

1994, 1995, 1996, 1997, 1998, 1999, 2000, 2001, 2002, 2003, 2004, 2005, 2006, 2007, 2008, 2009, 2010, 2011, 2012, 2013, 2014, 2015, 2016, 2017, 2018, 2019, 2020, 2021, 2022, 2023, 2024, 2025, 2026, 2027, 2028, 2029, 2030, 2031, 2032, 2033, 2034, 2035, 2036, 2037, 2038, 2039, 2040, 2041, 2042, 2043, 2044, 2045, 2046, 2047, 2048, 2049, 2050, 2051, 2052, 2053, 2054, 2055, 2056, 2057, 2058, 2059, 2060, 2061, 2062, 2063, 2064, 2065, 2066, 2067, 2068, 2069, 2070, 2071, 2072, 2073, 2074, 2075, 2076, 2077, 2078, 2079, 2080, 2081, 2082, 2083, 2084, 2085, 2086, 2087, 2088, 2089, 2090, 2091, 2092, 2093, 2094, 2095, 2096, 2097, 2098, 2099, 2100, 2101, 2102, 2103, 2104, 2105, 2106, 2107, 2108, 2109, 2110, 2111, 2112, 2113, 2114, 2115, 2116, 2117, 2118, 2119, 2120, 2121, 2122, 2123, 2124, 2125, 2126, 2127, 2128, 2129, 2130, 2131, 2132, 2133, 2134, 2135, 2136, 2137, 2138, 2139, 2140, 2141, 2142, 2143, 2144, 2145, 2146, 2147, 2148, 2149, 2150, 2151, 2152, 2153, 2154, 2155, 2156, 2157, 2158, 2159, 2160, 2161, 2162, 2163, 2164, 2165, 2166, 2167, 2168, 2169, 2170, 2171, 2172, 2173, 2174, 2175, 2176, 2177, 2178, 2179, 2180, 2181, 2182, 2183, 2184, 2185, 2186, 2187, 2188, 2189, 2190, 2191, 2192, 2193, 2194, 2195, 2196, 2197, 2198, 2199, 2200, 2201, 2202, 2203, 2204, 2205, 2206, 2207, 2208, 2209, 2210, 2211, 2212, 2213, 2214, 2215, 2216, 2217, 2218, 2219, 2220, 2221, 2222, 2223, 2224, 2225, 2226, 2227, 2228, 2229, 2230, 2231, 2232, 2233, 2234, 2235, 2236, 2237, 2238, 2239, 2240, 2241, 2242, 2243, 2244, 2245, 2246, 2247, 2248, 2249, 2250, 2251, 2252, 2253, 2254, 2255, 2256, 2257, 2258, 2259, 2260, 2261, 2262, 2263, 2264, 2265, 2266, 2267, 2268, 2269, 2270, 2271, 2272, 2273, 2274, 2275, 2276, 2277, 2278, 2279, 2280, 2281, 2282, 2283, 2284, 2285, 2286, 2287, 2288, 2289, 2290, 2291, 2292, 2293, 2294, 2295, 2296, 2297, 2298, 2299, 2300, 2301, 2302, 2303, 2304, 2305, 2306, 2307, 2308, 2309, 2310, 2311, 2312, 2313, 2314, 2315, 2316, 2317, 2318, 2319, 2320, 2321, 2322, 2323, 2324, 2325, 2326, 2327, 2328, 2329, 2330, 2331, 2332, 2333, 2334, 2335, 2336, 2337, 2338, 2339, 2340, 2341, 2342, 2343, 2344, 2345, 2346, 2347, 2348, 2349, 2350, 2351, 2352, 2353, 2354, 2355, 2356, 2357, 2358, 2359, 2360, 2361, 2362, 2363, 2364, 2365, 2366, 2367, 2368, 2369, 2370, 2371, 2372, 2373, 2374, 2375, 2376, 2377, 2378, 2379, 2380, 2381, 2382, 2383, 2384, 2385, 2386, 2387, 2388, 2389, 2390, 2391, 2392, 2393, 2394, 2395, 2396, 2397, 2398, 2399, 2400, 2401, 2402, 2403, 2404, 2405, 2406, 2407, 2408, 2409, 2410, 2411, 2412, 2413, 2414, 2415, 2416, 2417, 2418, 2419, 2420, 2421, 2422, 2423, 2424, 2425, 2426, 2427, 2428, 2429, 2430, 2431, 2432, 2433, 2434, 2435, 2436, 2437, 2438, 2439, 2440, 2441, 2442, 2443, 2444, 2445, 2446, 2447, 2448, 2449, 2450, 2451, 2452, 2453, 2454, 2455, 2456, 2457, 2458, 2459, 2460, 2461, 2462, 2463, 2464, 2465, 2466, 2467, 2468, 2469, 2470, 2471, 2472, 2473, 2474, 2475, 2476, 2477, 2478, 2479, 2480, 2481, 2482, 2483, 2484, 2485, 2486, 2487, 2488, 2489, 2490, 2491, 2492, 2493, 2494, 2495, 2496, 2497, 2498, 2499, 2500, 2501, 2502, 2503, 2504, 2505, 2506, 2507, 2508, 2509, 2510, 2511, 2512, 2513, 2514, 2515, 2516, 2517, 2518, 2519, 2520, 2521, 2522, 2523, 2524, 2525, 2526, 2527, 2528, 2529, 2530, 2531, 2532, 2533, 2534, 2535, 2536, 2537, 2538, 2539, 2540, 2541, 2542, 2543, 2544, 2545, 2546, 2547, 2548, 2549, 2550, 2551, 2552, 2553, 2554, 2555, 2556, 2557, 2558, 2559, 2560, 2561, 2562, 2563, 2564, 2565, 2566, 2567, 2568, 2569, 2570, 2571, 2572, 2573, 2574, 2575, 2576, 2577, 2578, 2579, 2580, 2581, 2582, 2583, 2584, 2585, 2586, 2587, 2588, 2589, 2590, 2591, 2592, 2593, 2594, 2595, 2596, 2597, 2598, 2599, 2600, 2601, 2602, 2603, 2604, 2605, 2606, 2607, 2608, 2609, 2610, 2611, 2612, 2613, 2614, 2615, 2616, 2617, 2618, 2619, 2620, 2621, 2622, 2623, 2624, 2625, 2626, 2627, 2628, 2629, 2630, 2631, 2632, 2633, 2634, 2635, 2636, 2637, 2638, 2639, 2640, 2641, 2642, 2643, 2644, 2645, 2646, 2647, 2648, 2649, 2650, 2651, 2652, 2653, 2654, 2655, 2656, 2657, 2658, 2659, 2660, 2661, 2662, 2663, 2664, 2665, 2666, 2667, 2668, 2669, 2670, 2671, 2672, 2673, 2674, 2675, 26

1,200,496	1,200,496
319,785	319,785

1,520,281 1,775,100

$$]] \vdash_{\text{L}} I_{\text{L}} \quad \vdash_{\text{L}}] \vdash_{\text{L}} \vdash_{\text{L}} I_{\text{L}} \rightarrow .]] \rightarrow \vdash_{\text{L}}] \vdash_{\text{L}}]] \vdash_{\text{L}} I_{\text{L}}$$

4. OTHER INCOME

2023 /
RMB'000 RMB'000

[illegible]

61,239

$$S = \{I_1, I_2, I_3, I_4\} \quad T = \{I_1, I_2, I_3, I_4, I_5, I_6, I_7, I_8, I_9, I_{10}, I_{11}, I_{12}\}$$

203 //

$$\mathbf{b}^T, \mathbf{1}^T, \mathbf{1}^T \mathbf{b}^T$$

463,538 100%

• The []

524,980

5. PROFIT BEFORE TAX

[illegible]

_____	_____
=====	=====

_____	_____
_____	_____
=====	_____

	2023	
	RMB'000	RMB'000
– 2023 年 12 月 31 日	529,206	1,414,746
– 2022 年 12 月 31 日	(159,702)	(2,211,242)
	<u>369,504</u>	<u>(796,496)</u>

Cash dividend

2023
RMB'000

RMB'000

721,548

[illegible]

11. TRADE AND BILLS RECEIVABLES

	2023 RMB'000	2022 RMB'000
Trade receivables	7,643,737	7,643,737
Bills receivable	24,492	24,492
	<u>7,668,229</u>	<u>7,668,229</u>
Less: Expected credit losses	(1,034,852)	(1,034,852)
Net trade and bills receivables	6,633,377	6,633,377
Trade receivables	7,643,737	7,643,737
Less: Expected credit losses	(1,034,852)	(1,034,852)
Net trade receivables	6,608,885	6,608,885
Bills receivable	24,492	24,492
Less: Expected credit losses	(0)	(0)
Net bills receivable	24,492	24,492
	<u>6,633,377</u>	<u>6,633,377</u>

12. TRADE AND BILLS PAYABLES

	2023 RMB'000	2022 RMB'000
Trade payables	5,507,366	5,507,366
Bills payable	652,253	652,253
	<u>6,159,619</u>	<u>6,159,619</u>
Trade payables	5,507,366	5,507,366
Less: Expected credit losses	(0)	(0)
Net trade payables	5,507,366	5,507,366
Bills payable	652,253	652,253
Less: Expected credit losses	(0)	(0)
Net bills payable	652,253	652,253
	<u>6,159,619</u>	<u>6,159,619</u>

MANAGEMENT DISCUSSION AND ANALYSIS

THE BOARD'S DISCUSSION AND ANALYSIS ON OPERATIONS OF THE GROUP FOR THE REPORTING PERIOD

I. MAIN OPERATIONAL PROGRESS OF THE GROUP DURING THE REPORTING PERIOD

1. Continued to promote the innovation transformation and the development and launch of innovative products

[illegible]

[illegible]

A complex musical score for a string quartet, featuring four staves with various musical notations including notes, rests, and dynamic markings. The score is written in a standard musical notation style, with a key signature of one flat (B-flat) and a common time signature (C). The notation includes a variety of note values, rests, and dynamic markings such as 'p' (piano) and 'f' (forte). The score is arranged in a traditional four-staff format, with each staff representing a different instrument in the quartet. The overall structure of the score suggests a multi-measure rest followed by a series of melodic and harmonic developments.

[illegible]

2. Continued to enhance global operation capabilities


[illegible]

A complex musical score for a string quartet, featuring four staves with various musical notations including notes, rests, and dynamic markings. The score is written in a standard musical notation style, with a key signature of one flat (B-flat) and a common time signature (C). The notation includes a variety of note values, rests, and dynamic markings such as 'p' (piano) and 'f' (forte). The score is presented in a single system, with the four staves arranged vertically. The notation is dense and intricate, with many notes and rests, suggesting a highly technical and expressive piece of music. The overall style is that of a classical or modernist string quartet score.


[illegible]

• *I e a a a e a e d c*


[illegible]



● *P e ba - a ce e c e a*



● *P e b d d c e e a a a a da d*



4. Matured commercialization system

— — —

一、本會之宗旨，在於研究我國經濟，以謀國家之富強，及國民生活之改善。凡我會員，應各盡其力，以達成此目的。

二、本會之組織，由會員大會、理事會、監事會、及秘書處等組成。會員大會為最高權力機關，理事會為執行機關，監事會為監督機關，秘書處為行政機關。

三、本會之經費，由會員會費、捐款、及政府補助等項充之。凡我會員，應各盡其力，以充實本會之經費。

四、本會之辦事處，設於本市。凡我會員，如有任何建議或意見，請隨時向本會秘書處提出。

五、本會之章程，業經會員大會通過，自公布之日起施行。

六、本會之會員，應各盡其力，以達成本會之宗旨。凡我會員，如有任何建議或意見，請隨時向本會秘書處提出。

七、本會之經費，由會員會費、捐款、及政府補助等項充之。凡我會員，應各盡其力，以充實本會之經費。

八、本會之辦事處，設於本市。凡我會員，如有任何建議或意見，請隨時向本會秘書處提出。

九、本會之章程，業經會員大會通過，自公布之日起施行。

十、本會之會員，應各盡其力，以達成本會之宗旨。凡我會員，如有任何建議或意見，請隨時向本會秘書處提出。

十一、本會之經費，由會員會費、捐款、及政府補助等項充之。凡我會員，應各盡其力，以充實本會之經費。

十二、本會之辦事處，設於本市。凡我會員，如有任何建議或意見，請隨時向本會秘書處提出。

十三、本會之章程，業經會員大會通過，自公布之日起施行。

十四、本會之會員，應各盡其力，以達成本會之宗旨。凡我會員，如有任何建議或意見，請隨時向本會秘書處提出。

十五、本會之經費，由會員會費、捐款、及政府補助等項充之。凡我會員，應各盡其力，以充實本會之經費。


十六、本會之辦事處，設於本市。凡我會員，如有任何建議或意見，請隨時向本會秘書處提出。


十七、本會之章程，業經會員大會通過，自公布之日起施行。

十八、本會之會員，應各盡其力，以達成本會之宗旨。凡我會員，如有任何建議或意見，請隨時向本會秘書處提出。

十九、本會之經費，由會員會費、捐款、及政府補助等項充之。凡我會員，應各盡其力，以充實本會之經費。





二十、本會之辦事處，設於本市。凡我會員，如有任何建議或意見，請隨時向本會秘書處提出。













Progress during the Reporting Period	Drug name/code	Target/mechanism	Drug Category	IND approved	Phase I	Phase II	Phase III	NDA accepted	Approved for launch	Remarks
	<p> $\text{C}_{12}\text{H}_{18}\text{N}_2\text{O}_4$ </p>			<p> $\text{C}_{12}\text{H}_{18}\text{N}_2\text{O}_4$ </p>						N 5
	<p> $\text{C}_{12}\text{H}_{18}\text{N}_2\text{O}_4$ </p>			<p> $\text{C}_{12}\text{H}_{18}\text{N}_2\text{O}_4$ </p>						—

Table 2: Major marketed innovative products and description of core categories

No.	Therapeutic area	Product name	Description of product	Photo of product
1	Infectious diseases	Novel anti-hepatitis B virus (HBV) drug	This is a novel anti-hepatitis B virus (HBV) drug, which is a nucleoside analogue. It is designed to inhibit the replication of HBV, thereby reducing the viral load and preventing liver damage. The drug is expected to be a significant breakthrough in the treatment of HBV, as current treatments are limited and often have side effects.	
2		Novel anti-hepatitis C virus (HCV) drug	This is a novel anti-hepatitis C virus (HCV) drug, which is a direct-acting antiviral (DAA). It is designed to inhibit the HCV protease, a key enzyme for viral replication. The drug is expected to be a significant breakthrough in the treatment of HCV, as current treatments are limited and often have side effects.	
3		Novel anti-hepatitis E virus (HEV) drug	This is a novel anti-hepatitis E virus (HEV) drug, which is a nucleoside analogue. It is designed to inhibit the replication of HEV, thereby reducing the viral load and preventing liver damage. The drug is expected to be a significant breakthrough in the treatment of HEV, as current treatments are limited and often have side effects.	
4		Novel anti-hepatitis A virus (HAV) drug	This is a novel anti-hepatitis A virus (HAV) drug, which is a nucleoside analogue. It is designed to inhibit the replication of HAV, thereby reducing the viral load and preventing liver damage. The drug is expected to be a significant breakthrough in the treatment of HAV, as current treatments are limited and often have side effects.	

No.	Therapeutic area	Product name	Description of product	Photo of product
4	糖尿病治疗	马来酸阿托伐他汀片	本品为白色片剂，用于降低血脂，预防心血管疾病。	
5		阿托伐他汀片	本品为白色片剂，用于降低血脂，预防心血管疾病。	
6		二甲双胍片	本品为白色片剂，用于降低血糖，预防糖尿病并发症。	
7		格列齐特片	本品为白色片剂，用于降低血糖，预防糖尿病并发症。	

No.	Therapeutic area	Product name	Description of product	Photo of product
1	呼吸系統	吸入性糖皮質類固醇	吸入性糖皮質類固醇是治療哮喘和慢性阻塞性肺病的主要藥物。它通過減少氣道炎症和腫脹，從而減輕症狀並防止發作。常見的副作用包括口腔念珠菌病和聲音嘶啞。	
2		吸入性β ₂ 受體激動劑	吸入性β ₂ 受體激動劑是治療哮喘和慢性阻塞性肺病的主要藥物。它通過鬆弛氣道平滑肌，從而減輕症狀並防止發作。常見的副作用包括心悸和手抖。	
3		吸入性長效β ₂ 受體激動劑	吸入性長效β ₂ 受體激動劑是治療哮喘和慢性阻塞性肺病的主要藥物。它通過鬆弛氣道平滑肌，從而減輕症狀並防止發作。常見的副作用包括心悸和手抖。	
4		吸入性抗膽碱能藥物	吸入性抗膽碱能藥物是治療哮喘和慢性阻塞性肺病的主要藥物。它通過阻斷膽碱能神經傳導，從而減輕症狀並防止發作。常見的副作用包括乾咳和頭痛。	

II. SEGMENT PERFORMANCE OVERVIEW

1. Pharmaceutical manufacturing

Pe a ce a

[illegible][illegible]

— *I* *I* *I* *I* *I*

— —

[illegible][illegible]

- $A \rightarrow r \rightarrow K$ - K r CAR-T K r r K r

[illegible]

[illegible]

一、 $\int_0^1 \frac{1}{x} dx$ 的收敛性
 二、 $\int_0^1 \frac{1}{x^2} dx$ 的收敛性
 三、 $\int_0^1 \frac{1}{x^3} dx$ 的收敛性
 四、 $\int_0^1 \frac{1}{x^4} dx$ 的收敛性
 五、 $\int_0^1 \frac{1}{x^5} dx$ 的收敛性
 六、 $\int_0^1 \frac{1}{x^6} dx$ 的收敛性
 七、 $\int_0^1 \frac{1}{x^7} dx$ 的收敛性
 八、 $\int_0^1 \frac{1}{x^8} dx$ 的收敛性
 九、 $\int_0^1 \frac{1}{x^9} dx$ 的收敛性
 十、 $\int_0^1 \frac{1}{x^{10}} dx$ 的收敛性

[illegible][illegible]

[illegible][illegible][illegible]

[illegible][illegible][illegible][illegible][illegible]



Table 5 — License-in innovative drugs

No.	Therapeutic area	Drug name/code	Indications	R&D progress in major licensed territory as at the end of the Reporting Period
1	Oncology	▲ 1. 2. 3. 4. 5. 6. 7. 8. 9. 10. 11. 12. 13. 14. 15. 16. 17. 18. 19. 20. 21. 22. 23. 24. 25. 26. 27. 28. 29. 30. 31. 32. 33. 34. 35. 36. 37. 38. 39. 40. 41. 42. 43. 44. 45. 46. 47. 48. 49. 50. 51. 52. 53. 54. 55. 56. 57. 58. 59. 60. 61. 62. 63. 64. 65. 66. 67. 68. 69. 70. 71. 72. 73. 74. 75. 76. 77. 78. 79. 80. 81. 82. 83. 84. 85. 86. 87. 88. 89. 90. 91. 92. 93. 94. 95. 96. 97. 98. 99. 100. 101. 102. 103. 104. 105. 106. 107. 108. 109. 110. 111. 112. 113. 114. 115. 116. 117. 118. 119. 120. 121. 122. 123. 124. 125. 126. 127. 128. 129. 130. 131. 132. 133. 134. 135. 136. 137. 138. 139. 140. 141. 142. 143. 144. 145. 146. 147. 148. 149. 150. 151. 152. 153. 154. 155. 156. 157. 158. 159. 160. 161. 162. 163. 164. 165. 166. 167. 168. 169. 170. 171. 172. 173. 174. 175. 176. 177. 178. 179. 180. 181. 182. 183. 184. 185. 186. 187. 188. 189. 190. 191. 192. 193. 194. 195. 196. 197. 198. 199. 200. 201. 202. 203. 204. 205. 206. 207. 208. 209. 210. 211. 212. 213. 214. 215. 216. 217. 218. 219. 220. 221. 222. 223. 224. 225. 226. 227. 228. 229. 230. 231. 232. 233. 234. 235. 236. 237. 238. 239. 240. 241. 242. 243. 244. 245. 246. 247. 248. 249. 250. 251. 252. 253. 254. 255. 256. 257. 258. 259. 260. 261. 262. 263. 264. 265. 266. 267. 268. 269. 270. 271. 272. 273. 274. 275. 276. 277. 278. 279. 280. 281. 282. 283. 284. 285. 286. 287. 288. 289. 290. 291. 292. 293. 294. 295. 296. 297. 298. 299. 300. 301. 302. 303. 304. 305. 306. 307. 308. 309. 310. 311. 312. 313. 314. 315. 316. 317. 318. 319. 320. 321. 322. 323. 324. 325. 326. 327. 328. 329. 330. 331. 332. 333. 334. 335. 336. 337. 338. 339. 340. 341. 342. 343. 344. 345. 346. 347. 348. 349. 350. 351. 352. 353. 354. 355. 356. 357. 358. 359. 360. 361. 362. 363. 364. 365. 366. 367. 368. 369. 370. 371. 372. 373. 374. 375. 376. 377. 378. 379. 380. 381. 382. 383. 384. 385. 386. 387. 388. 389. 390. 391. 392. 393. 394. 395. 396. 397. 398. 399. 400. 401. 402. 403. 404. 405. 406. 407. 408. 409. 410. 411. 412. 413. 414. 415. 416. 417. 418. 419. 420. 421. 422. 423. 424. 425. 426. 427. 428. 429. 430. 431. 432. 433. 434. 435. 436. 437. 438. 439. 440. 441. 442. 443. 444. 445. 446. 447. 448. 449. 450. 451. 452. 453. 454. 455. 456. 457. 458. 459. 460. 461. 462. 463. 464. 465. 466. 467. 468. 469. 470. 471. 472. 473. 474. 475. 476. 477. 478. 479. 480. 481. 482. 483. 484. 485. 486. 487. 488. 489. 490. 491. 492. 493. 494. 495. 496. 497. 498. 499. 500. 501. 502. 503. 504. 505. 506. 507. 508. 509. 510. 511. 512. 513. 514. 515. 516. 517. 518. 519. 520. 521. 522. 523. 524. 525. 526. 527. 528. 529. 530. 531. 532. 533. 534. 535. 536. 537. 538. 539. 540. 541. 542. 543. 544. 545. 546. 547. 548. 549. 550. 551. 552. 553. 554. 555. 556. 557. 558. 559. 560. 561. 562. 563. 564. 565. 566. 567. 568. 569. 570. 571. 572. 573. 574. 575. 576. 577. 578. 579. 580. 581. 582. 583. 584. 585. 586. 587. 588. 589. 590. 591. 592. 593. 594. 595. 596. 597. 598. 599. 600. 601. 602. 603. 604. 605. 606. 607. 608. 609. 610. 611. 612. 613. 614. 615. 616. 617. 618. 619. 620. 621. 622. 623. 624. 625. 626. 627. 628. 629. 630. 631. 632. 633. 634. 635. 636. 637. 638. 639. 640. 641. 642. 643. 644. 645. 646. 647. 648. 649. 650. 651. 652. 653. 654. 655. 656. 657. 658. 659. 660. 661. 662. 663. 664. 665. 666. 667. 668. 669. 670. 671. 672. 673. 674. 675. 676. 677. 678. 679. 680. 681. 682. 683. 684. 685. 686. 687. 688. 689. 690. 691. 692. 693. 694. 695. 696. 697. 698. 699. 700. 701. 702. 703. 704. 705. 706. 707. 708. 709. 710. 711. 712. 713. 714. 715. 716. 717. 718. 719. 720. 721. 722. 723. 724. 725. 726. 727. 728. 729. 730. 731. 732. 733. 734. 735. 736. 737. 738. 739. 740. 741. 742. 743. 744. 745. 746. 747. 748. 749. 750. 751. 752. 753. 754. 755. 756. 757. 758. 759. 760. 761. 762. 763. 764. 765. 766. 767. 768. 769. 770. 771. 772. 773. 774. 775. 776. 777. 778. 779. 780. 781. 782. 783. 784. 785. 786. 787. 788. 789. 790. 791. 792. 793. 794. 795. 796. 797. 798. 799. 800. 801. 802. 803. 804. 805. 806. 807. 808. 809. 810. 811. 812. 813. 814. 815. 816. 817. 818. 819. 820. 821. 822. 823. 824. 825. 826. 827. 828. 829. 830. 831. 832. 833. 834. 835. 836. 837. 838. 839. 840. 841. 842. 843. 844. 845. 846. 847. 848. 849. 850. 851. 852. 853. 854. 855. 856. 857. 858. 859. 860. 861. 862. 863. 864. 865. 866. 867. 868. 869. 870. 871. 872. 873. 874. 875. 876. 877. 878. 879. 880. 881. 882. 883. 884. 885. 886. 887. 888. 889. 890. 891. 892. 893. 894. 895. 896. 897. 898. 899. 900. 901. 902. 903. 904. 905. 906. 907. 908. 909. 910. 911. 912. 913. 914. 915. 916. 917. 918. 919. 920. 921. 922. 923. 924. 925. 926. 927. 928. 929. 930. 931. 932. 933. 934. 935. 936. 937. 938. 939. 940. 941. 942. 943. 944. 945. 946. 947. 948. 949. 950. 951. 952. 953. 954. 955. 956. 957. 958. 959. 960. 961. 962. 963. 964. 965. 966. 967. 968. 969. 970. 971. 972. 973. 974. 975. 976. 977. 978. 979. 980. 981. 982. 983. 984. 985. 986. 987. 988. 989. 990. 991. 992. 993. 994. 995. 996. 997. 998. 999. 1000. 1001. 1002. 1003. 1004. 1005. 1006. 1007. 1008. 1009. 1010. 1011. 1012. 1013. 1014. 1015. 1016. 1017. 1018. 1019. 1020. 1021. 1022. 1023. 1024. 1025. 1026. 1027. 1028. 1029. 1030. 1031. 1032. 1033. 1034. 1035. 1036. 1037. 1038. 1039. 1040. 1041. 1042. 1043. 1044. 1045. 1046. 1047. 1048. 1049. 1050. 1051. 1052. 1053. 1054. 1055. 1056. 1057. 1058. 1059. 1060. 1061. 1062. 1063. 1064. 1065. 1066. 1067. 1068. 1069. 1070. 1071. 1072. 1073. 1074. 1075. 1076. 1077. 1078. 1079. 1080. 1081. 1082. 1083. 1084. 1085. 1086. 1087. 1088. 1089. 1090. 1091. 1092. 1093. 1094. 1095. 1096. 1097. 1098. 1099. 1100. 1101. 1102. 1103. 1104. 1105. 1106. 1107. 1108. 1109. 1110. 1111. 1112. 1113. 1114. 1115. 1116. 1117. 1118. 1119. 1120. 1121. 1122. 1123. 1124. 1125. 1126. 1127. 1128. 1129. 1130. 1131. 1132. 1133. 1134. 1135. 1136. 1137. 1138. 1139. 1140. 1141. 1142. 1143. 1144. 1145. 1146. 1147. 1148. 1149. 1150. 1151. 1152. 1153. 1154. 1155. 1156. 1157. 1158. 1159. 1160. 1161. 1162. 1163. 1164. 1165. 1166. 1167. 1168. 1169. 1170. 1171. 1172. 1173. 1174. 1175. 1176. 1177. 1178. 1179. 1180. 1181. 1182. 1183. 1184. 1185. 1186. 1187. 1188. 1189. 1190. 1191. 1192. 1193. 1194. 1195. 1196. 1197. 1198. 1199. 1200. 1201. 1202. 1203. 1204. 1205. 1206. 1207. 1208. 1209. 1210. 1211. 1212. 1213. 1214. 1215. 1216. 1217. 1218. 1219. 1220. 1221. 1222. 1223. 1224. 1225. 1226. 1227. 1228. 1229. 1230. 1231. 1232. 1233. 1234. 1235. 1236. 1237. 1238. 1239. 1240. 1241. 1242. 1243. 1244. 1245. 1246. 1247. 1248. 1249. 1250. 1251. 1252. 1253. 1254. 1255. 1256. 1257. 1258. 1259. 1260. 1261. 1262. 1263. 1264. 1265. 1266. 1267. 1268. 1269. 1270. 1271. 1272. 1273. 1274. 1275. 1276. 1277. 1278. 1279. 1280. 1281. 1282. 1283. 1284. 1285. 1286. 1287. 1288. 1289. 1290. 1291. 1292. 1293. 1294. 1295. 1296. 1297. 1298. 1299. 1300. 1301. 1302. 1303. 1304. 1305. 1306. 1307. 1308. 1309. 1310. 1311. 1312. 1313. 1314. 1315. 1316. 1317. 1318. 1319. 1320. 1321. 1322. 1323. 1324. 1325. 1326. 1327. 1328. 1329. 1330. 1331. 1332. 1333. 1334. 1335. 1336. 1337. 1338. 1339. 1340. 1341. 1342. 1343. 1344. 1345. 1346. 1347. 1348. 1349. 1350. 1351. 1352. 1353. 1354. 1355. 1356. 1357. 1358. 1359. 1360. 1361. 1362. 1363. 1364. 1365. 1366. 1367. 1368. 1369. 1370. 1371. 1372. 1373. 1374. 1375. 1376. 1377. 1378. 1379. 1380. 1381. 1382. 1383. 1384. 1385. 1386. 1387. 1388. 1389. 1390. 1391. 1392. 1393. 1394. 1395. 1396. 1397. 1398. 1399. 1400. 1401. 1402. 1403. 1404. 1405. 1406. 1407. 1408. 1409. 1410. 1411. 1412. 1413. 1414. 1415. 1416. 1417. 1418. 1419. 1420. 1421. 1422. 1423. 1424. 1425. 1426. 1427. 1428. 1429. 1430. 1431. 1432. 1433. 1434. 1435. 1436. 1437. 1438. 1439. 1440. 1441. 1442. 1443. 1444. 1445. 1446. 1447. 1448. 1449. 1450. 1451. 1452. 1453. 1454. 1455. 1456. 1457. 1458. 1459. 1460. 1461. 1462. 1463. 1464. 1465. 1466. 1467. 1468. 1469. 1470. 1471. 1472. 1473. 1474. 1475. 1476. 1477. 1478. 1479. 1480. 1481. 1482. 1483. 1484. 1485. 1486. 1487. 1488. 1489. 1490. 1491. 1492. 1493. 1494. 1495. 1496. 1497. 1498. 1499. 1500. 1501. 1502. 1503. 1504. 1505. 1506. 1507. 1508. 1509. 1510. 1511. 1512. 1513. 1514. 1515. 1516. 1517. 1518. 1519. 1520. 1521. 1522. 1523. 1524. 1525. 1526. 1527. 1528. 1529. 1530. 1531. 1532. 1533. 1534. 1535. 1536. 1537. 1538. 1539. 1540. 1541. 1542. 1543. 1544. 1545. 1546. 1547. 1548. 1549. 1550. 1551. 1552. 1553. 1554. 1555. 1556. 1557. 1558. 1559. 1560. 1561. 1562. 1563. 1564. 1565. 1566. 1567. 1568. 1569. 1570. 1571. 1572. 1573. 1574. 1575. 1576. 1577. 1578. 1579. 1580. 1581. 1582. 1583. 1584. 1585. 1586. 1587. 1588. 1589. 1590. 1591. 1592. 1593. 1594. 1595. 1596. 1597. 1598. 1599. 1600. 1601. 1602. 1603. 1604. 1605. 1606. 1607. 1608. 1609. 1610. 1611. 1612. 1613. 1614. 1615. 1616. 1617. 1618. 1619. 1620. 1621. 1622. 1623. 1624. 1625. 1626. 1627. 1628. 1629. 1630. 1631. 1632. 1633. 1634. 1635. 1636. 1637. 1638. 1639. 1640. 1641. 1642. 1643. 1644. 1645. 1646. 1647. 1648. 1649. 1650. 1651. 1652. 1653. 1654. 1655. 1656. 1657. 1658. 1659. 1660. 1661. 1662. 1663. 1664. 1665. 1666. 1667. 1668. 1669. 1670. 1671. 1672. 1673. 1674. 1675. 1676. 1677. 1678. 1679. 1680. 1681. 1682. 1683. 1684. 1685. 1686. 1687. 1688. 1689. 1690. 1691. 1692. 1693. 1694. 1695. 1696. 1697. 1698. 1699. 1700. 1701. 1702. 1703. 1704. 1705. 1706. 1707. 1708. 1709. 1710. 1711. 1712. 1713. 1714. 1715. 1716. 1717. 1718. 1719. 1720. 1721. 1722. 1723. 1724. 1725. 1726. 1727. 1728. 1729. 1730. 1731. 1732. 1733. 1734. 1735. 1736. 1737. 1738. 1739. 1740. 1741. 1742. 1743. 1744. 1745. 1746. 1747. 1748. 1749. 1750. 1751. 1752. 1753. 1754. 1755. 1756. 1757. 1758. 1759. 1760. 1761. 1762. 1763. 1764. 1765. 1766. 1767. 1768. 1769. 1770. 1771. 1772. 1773. 1774. 1775. 1776. 1777. 1778. 1779. 1780. 1781. 1782. 1783. 1784. 1785. 1786. 1787. 1788. 1789. 1790. 1791. 1792. 1793. 1794. 1795. 1796. 1797. 1798. 1799. 1800. 1801. 1802. 1803. 1804. 1805. 1806. 1807. 1808. 1809. 1810. 1811. 1812. 1813. 1814. 1815. 1816. 1817. 1818. 1819. 1820. 1821. 1822. 1823. 1824. 1825. 1826. 1827. 1828. 1829. 1830. 1831. 1832. 1833. 1834. 1835. 1836. 1837. 1838. 1839. 1840. 1841. 1842. 1843. 1844. 1845. 1846. 1847. 1848. 1849. 1850. 1851. 1852. 1853. 1854. 1855. 1856. 1857. 1858. 1859. 1860. 1861. 1862. 1863. 1864. 1865. 1866. 1867. 1868. 1869. 1870. 1871. 1872. 1873. 1874. 1875. 1876. 1877. 1878. 1879. 1880. 1881. 1882. 1883. 1884. 1885. 1886. 1887. 1888. 1889. 1890. 1891. 1892. 1893. 1894. 1895. 1896. 1897. 1898. 1899. 1900. 1901. 1902. 1903. 1904. 1905. 1906. 1907. 1908. 1909. 1910. 1911. 1912. 1913. 1914. 1915. 1916. 1917. 1918. 1919. 1920. 1921. 1922. 1923. 1924. 1925. 1926. 1927. 1928. 1929. 1930. 1931. 1932. 1933. 1934. 1935. 1936. 1937. 1938. 1939. 1940. 1941. 1942. 1943. 1944. 1945. 1946. 1947. 1948. 1949. 1950. 1951. 1952. 1953. 1954. 1955. 1956. 1957. 1958. 1959. 1960. 1961. 1962. 1963. 1964. 1965. 1966. 1967. 1968. 1969. 1970. 1971. 1972. 1973. 1974. 1975. 1976. 1977. 1978. 1979. 1980. 1981. 1982. 1983. 1984. 1985. 1986. 1987. 1988. 1989. 1990. 1991. 1992. 1993. 1994. 1995. 1996. 1997. 1998. 1999. 2000. 2001. 2002. 2003. 2004. 2005. 2006. 2007. 2008. 2009. 2010. 2011. 2012. 2013. 2014. 2015. 2016. 2017. 2018. 2019. 2020. 2021. 2022. 2023. 2024. 2025. 2026. 2027. 2028. 2029. 2030. 2031. 2032. 2033. 2034. 2035. 2036. 2037. 2038. 2039. 2040. 2041. 2042. 2043. 2044. 2045. 2046. 2047. 2048. 2049. 2050. 2051. 2052. 2053. 2054. 2055. 2056. 2057. 2058. 2059. 2060. 2061. 2062. 2063. 2064. 2065. 2066. 2067. 2068. 2069. 2070. 2071. 2072. 2073. 2074. 2075. 2076. 2077. 2078. 2079. 2080. 2081. 2082. 2083. 2084. 2085. 2086. 2087. 2088. 2089. 2090. 2091. 2092. 2093. 2094. 2095. 2096. 2097. 2098. 2099. 2100. 2101. 2102. 2103. 2104. 2105. 2106. 2107. 2108. 2109. 2110. 2111. 2112. 2113. 2114. 2115. 2116. 2117. 2118. 2119. 2120. 2121. 2122. 2123. 2124. 2125. 2126. 2127. 2128. 2129. 2130. 2131. 2132. 2133. 2134. 2135. 2136. 2137. 2138. 2139. 2140. 2141. 2142. 2143. 2144. 2145. 2146. 2147. 2148. 2149. 2150. 2151. 2152. 2153. 2154. 2155. 2156. 2157. 2158. 2159. 2160. 2161. 2162. 2163. 2164. 2165. 2166. 2167. 2168. 2169. 2170. 2171. 2172. 2173. 2174. 2175. 2176. 2177. 2178. 2179. 2180. 2181. 2182. 2183. 2184. 2185. 2186. 2187. 2188. 2189. 2190. 2191. 2192. 2193. 2194. 2195. 2196. 2197. 2198. 2199. 2200. 2201. 2202. 2203. 2204. 2205. 2206. 2207. 2208. 2209. 2210. 2211. 2212. 2213. 2214. 2215. 2216. 2217. 2218. 2219. 2220. 2221. 22		

Table 6 — Biosimilars under independent development

[illegible][illegible]

—*(The music continues with various instruments playing notes and rests.)*

Table 7 — Products won tenders for centralized procurement

No.	Round selected	Name of drugs	Indications	Specifications	Charge unit
1	1	100 mg/ml	100 mg/ml	100 mg/ml	100 mg/ml
2		100 mg/ml	100 mg/ml	100 mg/ml	100 mg/ml
3	1	100 mg/ml	100 mg/ml	100 mg/ml	100 mg/ml
4		100 mg/ml	100 mg/ml	100 mg/ml	100 mg/ml
5		100 mg/ml	100 mg/ml	100 mg/ml	100 mg/ml
6		100 mg/ml	100 mg/ml	100 mg/ml	100 mg/ml
7	1	100 mg/ml	100 mg/ml	100 mg/ml	100 mg/ml
8		100 mg/ml	100 mg/ml	100 mg/ml	100 mg/ml
9		100 mg/ml	100 mg/ml	100 mg/ml	100 mg/ml
10		100 mg/ml	100 mg/ml	100 mg/ml	100 mg/ml
11		100 mg/ml	100 mg/ml	100 mg/ml	100 mg/ml
12		100 mg/ml	100 mg/ml	100 mg/ml	100 mg/ml
13	1	100 mg/ml	100 mg/ml	100 mg/ml	100 mg/ml
14		100 mg/ml	100 mg/ml	100 mg/ml	100 mg/ml
15		100 mg/ml	100 mg/ml	100 mg/ml	100 mg/ml
16		100 mg/ml	100 mg/ml	100 mg/ml	100 mg/ml
17		100 mg/ml	100 mg/ml	100 mg/ml	100 mg/ml
18		100 mg/ml	100 mg/ml	100 mg/ml	100 mg/ml
19	1	100 mg/ml	100 mg/ml	100 mg/ml	100 mg/ml
20		100 mg/ml	100 mg/ml	100 mg/ml	100 mg/ml
21		100 mg/ml	100 mg/ml	100 mg/ml	100 mg/ml
22		100 mg/ml	100 mg/ml	100 mg/ml	100 mg/ml
23		100 mg/ml	100 mg/ml	100 mg/ml	100 mg/ml
24		100 mg/ml	100 mg/ml	100 mg/ml	100 mg/ml
25	1	100 mg/ml	100 mg/ml	100 mg/ml	100 mg/ml
26		100 mg/ml	100 mg/ml	100 mg/ml	100 mg/ml
27		100 mg/ml	100 mg/ml	100 mg/ml	100 mg/ml
28		100 mg/ml	100 mg/ml	100 mg/ml	100 mg/ml
29		100 mg/ml	100 mg/ml	100 mg/ml	100 mg/ml
30		100 mg/ml	100 mg/ml	100 mg/ml	100 mg/ml
31	1	100 mg/ml	100 mg/ml	100 mg/ml	100 mg/ml
32		100 mg/ml	100 mg/ml	100 mg/ml	100 mg/ml
33		100 mg/ml	100 mg/ml	100 mg/ml	100 mg/ml
34		100 mg/ml	100 mg/ml	100 mg/ml	100 mg/ml
35		100 mg/ml	100 mg/ml	100 mg/ml	100 mg/ml
36		100 mg/ml	100 mg/ml	100 mg/ml	100 mg/ml
37	1	100 mg/ml	100 mg/ml	100 mg/ml	100 mg/ml
38		100 mg/ml	100 mg/ml	100 mg/ml	100 mg/ml
39		100 mg/ml	100 mg/ml	100 mg/ml	100 mg/ml
40		100 mg/ml	100 mg/ml	100 mg/ml	100 mg/ml
41		100 mg/ml	100 mg/ml	100 mg/ml	100 mg/ml
42		100 mg/ml	100 mg/ml	100 mg/ml	100 mg/ml
43	1	100 mg/ml	100 mg/ml	100 mg/ml	100 mg/ml
44		100 mg/ml	100 mg/ml	100 mg/ml	100 mg/ml
45		100 mg/ml	100 mg/ml	100 mg/ml	100 mg/ml
46		100 mg/ml	100 mg/ml	100 mg/ml	100 mg/ml
47		100 mg/ml	100 mg/ml	100 mg/ml	100 mg/ml
48		100 mg/ml	100 mg/ml	100 mg/ml	100 mg/ml
49	1	100 mg/ml	100 mg/ml	100 mg/ml	100 mg/ml
50		100 mg/ml	100 mg/ml	100 mg/ml	100 mg/ml
51		100 mg/ml	100 mg/ml	100 mg/ml	100 mg/ml
52		100 mg/ml	100 mg/ml	100 mg/ml	100 mg/ml
53		100 mg/ml	100 mg/ml	100 mg/ml	100 mg/ml
54		100 mg/ml	100 mg/ml	100 mg/ml	100 mg/ml
55	1	100 mg/ml	100 mg/ml	100 mg/ml	100 mg/ml
56		100 mg/ml	100 mg/ml	100 mg/ml	100 mg/ml
57		100 mg/ml	100 mg/ml	100 mg/ml	100 mg/ml
58		100 mg/ml	100 mg/ml	100 mg/ml	100 mg/ml
59		100 mg/ml	100 mg/ml	100 mg/ml	100 mg/ml
60		100 mg/ml	100 mg/ml	100 mg/ml	100 mg/ml

[illegible]

2. Medical Devices and Medical Diagnosis

①
②

Med ca De ce

...

[illegible][illegible]

“Ion System”

[illegible][illegible]

[illegible]

4. Pharmaceutical Distribution and Retail

[illegible][illegible][illegible][illegible]

5. Financing

III. CORE COMPETENCE ANALYSIS

IV. MAJOR OPERATIONS IN THE REPORTING PERIOD

(I) Analysis on Principal Operations

1. *A a C a e R e a I e I c e S a e e a d S a e e C a F*

Items	Amount for the year	Amount for last year	Year-on- year change	R	
1. <i>...</i>	N	1
2. <i>...</i>	N	1
3. <i>...</i>	N	2
4. <i>...</i>	N	3
5. <i>...</i>	N	4
6. <i>...</i>	N	5
7. <i>...</i>	N	5
8. <i>...</i>	N	6
9. <i>...</i>	N	7
<p><i>N 1: ...</i></p>					
<p><i>N 2: ...</i></p>					

Principal Operations by Products

[illegible]

Principal Operations by Geographical Locations

By geographical locations	Revenue	Cost of sales	Gross profit margin (%)	Year-on-year change in revenue (%)	Year-on-year change in cost of sales (%)	Year-on-year change in gross margin
China	1,234,567	789,012	35.6%	12.3%	8.7%	1.6%
North America	987,654	654,321	33.8%	15.2%	10.1%	5.1%
Europe	876,543	543,210	37.5%	9.8%	6.4%	3.4%
Asia (excl. China)	765,432	432,109	43.4%	18.7%	12.5%	6.2%
Latin America	654,321	321,098	50.6%	7.5%	4.2%	3.3%
Middle East & Africa	543,210	210,987	60.9%	5.3%	2.1%	3.2%
Oceania	432,109	109,876	74.3%	3.2%	1.5%	1.7%
Other	321,098	98,765	69.4%	2.1%	0.8%	1.3%
Total	5,835,334	3,515,568	39.6%	10.5%	6.5%	4.0%

[illegible]

4. R&D E d e

$$AKK \quad r \quad r_i \quad R\&D \quad r$$

藥品註冊管理辦法

R&D Expenditures

[illegible]

(II) Assets and liabilities analysis

Table 1. Assets and liabilities analysis of the company for the period from 2017 to 2019. The table shows the changes in the company's assets and liabilities over the three-year period. The assets are divided into fixed assets and current assets, while the liabilities are divided into long-term liabilities and short-term liabilities. The table also shows the percentage of each item relative to the total assets and liabilities.

Assets and liabilities

Items	Assets and liabilities					Reasons
	Amount as at the end of the period	Percentage of the amount as at the end of the period to the total asset (%)	Amount as at the end of last period	Percentage of the amount as at the end of last period to the total assets (%)	Ratio of change for the amount as at the end of the period as compared with the amount as at the end of last period (%)	
Fixed assets	1,111,111	100	1,111,111	100	100	Fixed assets
Current assets	1,111,111	100	1,111,111	100	100	Current assets
Long-term liabilities	1,111,111	100	1,111,111	100	100	Long-term liabilities
Short-term liabilities	1,111,111	100	1,111,111	100	100	Short-term liabilities
Equity	1,111,111	100	1,111,111	100	100	Equity
Retained earnings	1,111,111	100	1,111,111	100	100	Retained earnings
Dividends payable	1,111,111	100	1,111,111	100	100	Dividends payable
Accounts payable	1,111,111	100	1,111,111	100	100	Accounts payable
Accounts receivable	1,111,111	100	1,111,111	100	100	Accounts receivable
Inventory	1,111,111	100	1,111,111	100	100	Inventory
Prepaid expenses	1,111,111	100	1,111,111	100	100	Prepaid expenses
Other assets	1,111,111	100	1,111,111	100	100	Other assets
Other liabilities	1,111,111	100	1,111,111	100	100	Other liabilities
Other equity	1,111,111	100	1,111,111	100	100	Other equity

(III)Analysis on Subsidiaries and Investees

Other Related Matters or Gr

... ..

Name of subsidiary	Major business	Registered capital	Total assets	Net assets	Revenue	Operating profit	Net profit
...
...
...
...
...

N :

N 1:

N 2:

... ..

Name of subsidiary	Major business	Registered capital	Total assets	Net assets	Revenue	Net profit
--------------------	----------------	--------------------	--------------	------------	---------	------------

$$-1/2 \leq \beta \leq 1/2 \quad \text{and} \quad 0 \leq \alpha \leq 1 \quad \text{with} \quad \alpha + \beta = 1/2.$$
[illegible]

(IV) Employees and Remuneration Policies

[illegible]

THE BOARD'S DISCUSSION AND ANALYSIS ON FUTURE DEVELOPMENT OF THE GROUP

I. Industry Landscape and Trends

The Group's business operations are primarily concentrated in the construction and real estate sectors. In the construction sector, the Group has established a comprehensive project management system, covering the entire process from project acquisition to project completion. The Group has successfully completed a number of large-scale projects, including the construction of high-rise buildings, commercial complexes, and infrastructure projects. The Group's construction business has achieved significant growth in recent years, with a steady increase in the number of projects and the total value of construction contracts. The Group's real estate business is also performing well, with a strong focus on the development and operation of commercial real estate. The Group has successfully completed a number of large-scale real estate projects, including the development of commercial complexes, office buildings, and retail centers. The Group's real estate business has achieved significant growth in recent years, with a steady increase in the number of projects and the total value of real estate assets.

The Group's business operations are primarily concentrated in the construction and real estate sectors. In the construction sector, the Group has established a comprehensive project management system, covering the entire process from project acquisition to project completion. The Group has successfully completed a number of large-scale projects, including the construction of high-rise buildings, commercial complexes, and infrastructure projects. The Group's construction business has achieved significant growth in recent years, with a steady increase in the number of projects and the total value of construction contracts. The Group's real estate business is also performing well, with a strong focus on the development and operation of commercial real estate. The Group has successfully completed a number of large-scale real estate projects, including the development of commercial complexes, office buildings, and retail centers. The Group's real estate business has achieved significant growth in recent years, with a steady increase in the number of projects and the total value of real estate assets.

II. Corporate Development Strategies

[illegible]

III. Operation Plan

[illegible][illegible]

P a a c e c a M a a c

[illegible][illegible]

Med ca De ce a d Med ca Da

[illegible][illegible]

Hea ca e Se ce

[illegible]

P a a c e c a D b a d R e a

[illegible]

F a c

[illegible]

IV. Potential Risks

(I) Industry policies adjustments

[illegible][illegible]

1. 公司 2019 年度 研发投入 10,000 万元，较 2018 年度增加 2,000 万元，增幅为 25%。研发投入增加的主要原因是：公司 2019 年度在 5G 通信、人工智能、云计算、大数据、物联网、区块链、网络安全、智能制造等领域加大研发投入，重点开展 5G 通信、人工智能、云计算、大数据、物联网、区块链、网络安全、智能制造等领域的研发工作，重点开展 5G 通信、人工智能、云计算、大数据、物联网、区块链、网络安全、智能制造等领域的研发工作。

2. 公司 2019 年度 研发投入 10,000 万元，较 2018 年度增加 2,000 万元，增幅为 25%。研发投入增加的主要原因是：公司 2019 年度在 5G 通信、人工智能、云计算、大数据、物联网、区块链、网络安全、智能制造等领域加大研发投入，重点开展 5G 通信、人工智能、云计算、大数据、物联网、区块链、网络安全、智能制造等领域的研发工作，重点开展 5G 通信、人工智能、云计算、大数据、物联网、区块链、网络安全、智能制造等领域的研发工作。

(III) Business and operating risks

1. R&D risk

1. 公司 2019 年度 研发投入 10,000 万元，较 2018 年度增加 2,000 万元，增幅为 25%。研发投入增加的主要原因是：公司 2019 年度在 5G 通信、人工智能、云计算、大数据、物联网、区块链、网络安全、智能制造等领域加大研发投入，重点开展 5G 通信、人工智能、云计算、大数据、物联网、区块链、网络安全、智能制造等领域的研发工作，重点开展 5G 通信、人工智能、云计算、大数据、物联网、区块链、网络安全、智能制造等领域的研发工作。

2. 公司 2019 年度 研发投入 10,000 万元，较 2018 年度增加 2,000 万元，增幅为 25%。研发投入增加的主要原因是：公司 2019 年度在 5G 通信、人工智能、云计算、大数据、物联网、区块链、网络安全、智能制造等领域加大研发投入，重点开展 5G 通信、人工智能、云计算、大数据、物联网、区块链、网络安全、智能制造等领域的研发工作，重点开展 5G 通信、人工智能、云计算、大数据、物联网、区块链、网络安全、智能制造等领域的研发工作。

1. C = r / r = r / K / r = K / r

1. 公司 2019 年度 研发投入 10,000 万元，较 2018 年度增加 2,000 万元，增幅为 25%。研发投入增加的主要原因是：公司 2019 年度在 5G 通信、人工智能、云计算、大数据、物联网、区块链、网络安全、智能制造等领域加大研发投入，重点开展 5G 通信、人工智能、云计算、大数据、物联网、区块链、网络安全、智能制造等领域的研发工作，重点开展 5G 通信、人工智能、云计算、大数据、物联网、区块链、网络安全、智能制造等领域的研发工作。

2. 公司 2019 年度 研发投入 10,000 万元，较 2018 年度增加 2,000 万元，增幅为 25%。研发投入增加的主要原因是：公司 2019 年度在 5G 通信、人工智能、云计算、大数据、物联网、区块链、网络安全、智能制造等领域加大研发投入，重点开展 5G 通信、人工智能、云计算、大数据、物联网、区块链、网络安全、智能制造等领域的研发工作，重点开展 5G 通信、人工智能、云计算、大数据、物联网、区块链、网络安全、智能制造等领域的研发工作。

[illegible]

(IV) Management risks

$$\frac{1}{R} \frac{dR}{dt} = \frac{1}{r} \frac{dr}{dt}$$

$\frac{1}{\sqrt{\pi}} \int_{-\infty}^{\infty} f(x) \delta(x-a) dx = f(a)$

[illegible]
$$R \quad r \quad r_1 \quad r_2 \quad r \quad r, \quad K \quad r \quad r \quad K \quad r$$
[illegible]

(V) Foreign exchange risks

$\nabla \left[\frac{1}{\rho} \right] = - \frac{1}{\rho^2} \frac{\partial \rho}{\partial x_i} \frac{\partial \rho}{\partial x_j} \frac{\partial \rho}{\partial x_k} \dots$

III. Increase in Shareholding by a Controlling Shareholder

On 2022, the Company's controlling shareholder, the Company's subsidiary, and the Company's director and senior management have implemented the "Shareholding Increase Plan" to increase the shareholding of the Company's controlling shareholder, the Company's subsidiary, and the Company's director and senior management. The "Shareholding Increase Plan" is as follows:

The Company's controlling shareholder, the Company's subsidiary, and the Company's director and senior management have implemented the "Shareholding Increase Plan" to increase the shareholding of the Company's controlling shareholder, the Company's subsidiary, and the Company's director and senior management. The "Shareholding Increase Plan" is as follows:

The Company's controlling shareholder, the Company's subsidiary, and the Company's director and senior management have implemented the "Shareholding Increase Plan" to increase the shareholding of the Company's controlling shareholder, the Company's subsidiary, and the Company's director and senior management. The "Shareholding Increase Plan" is as follows:

IV. 2022 Restricted A Share Incentive Scheme

The Company's 2022 Restricted A Share Incentive Scheme is as follows:

The Company's 2022 Restricted A Share Incentive Scheme is as follows:

The Company's 2022 Restricted A Share Incentive Scheme is as follows:

1. The Company's 2022 Restricted A Share Incentive Scheme is as follows:

[illegible]

V. 2022 H Share Employee Share Ownership Scheme

[illegible]

REPURCHASE, SALE OR REDEMPTION OF THE COMPANY'S LISTED SECURITIES

2022 Restricted A Share Incentive Scheme

Sell back of “21 Fosun 01” Corporate Bonds

”《上海復星醫藥(集團)股份有限公司2019年公開發行公司債券(第一期)募集說明書(面向專業投資者)》

[illegible]

COMPLIANCE WITH THE CG CODE

1. The first part of the code is the title page, which contains the title, author, and date. The title is "COMPLIANCE WITH THE CG CODE", the author is "J. J. J.", and the date is "1999".

2. The second part of the code is the table of contents, which lists the chapters and their page numbers. The chapters are: "1. Introduction", "2. The CG Code", "3. The CG Code", "4. The CG Code", "5. The CG Code", "6. The CG Code", "7. The CG Code", "8. The CG Code", "9. The CG Code", "10. The CG Code", "11. The CG Code", "12. The CG Code", "13. The CG Code", "14. The CG Code", "15. The CG Code", "16. The CG Code", "17. The CG Code", "18. The CG Code", "19. The CG Code", "20. The CG Code", "21. The CG Code", "22. The CG Code", "23. The CG Code", "24. The CG Code", "25. The CG Code", "26. The CG Code", "27. The CG Code", "28. The CG Code", "29. The CG Code", "30. The CG Code", "31. The CG Code", "32. The CG Code", "33. The CG Code", "34. The CG Code", "35. The CG Code", "36. The CG Code", "37. The CG Code", "38. The CG Code", "39. The CG Code", "40. The CG Code", "41. The CG Code", "42. The CG Code", "43. The CG Code", "44. The CG Code", "45. The CG Code", "46. The CG Code", "47. The CG Code", "48. The CG Code", "49. The CG Code", "50. The CG Code", "51. The CG Code", "52. The CG Code", "53. The CG Code", "54. The CG Code", "55. The CG Code", "56. The CG Code", "57. The CG Code", "58. The CG Code", "59. The CG Code", "60. The CG Code", "61. The CG Code", "62. The CG Code", "63. The CG Code", "64. The CG Code", "65. The CG Code", "66. The CG Code", "67. The CG Code", "68. The CG Code", "69. The CG Code", "70. The CG Code", "71. The CG Code", "72. The CG Code", "73. The CG Code", "74. The CG Code", "75. The CG Code", "76. The CG Code", "77. The CG Code", "78. The CG Code", "79. The CG Code", "80. The CG Code", "81. The CG Code", "82. The CG Code", "83. The CG Code", "84. The CG Code", "85. The CG Code", "86. The CG Code", "87. The CG Code", "88. The CG Code", "89. The CG Code", "90. The CG Code", "91. The CG Code", "92. The CG Code", "93. The CG Code", "94. The CG Code", "95. The CG Code", "96. The CG Code", "97. The CG Code", "98. The CG Code", "99. The CG Code", "100. The CG Code".

3. The third part of the code is the list of figures, which contains the titles and page numbers of the figures. The figures are: "1. Figure 1", "2. Figure 2", "3. Figure 3", "4. Figure 4", "5. Figure 5", "6. Figure 6", "7. Figure 7", "8. Figure 8", "9. Figure 9", "10. Figure 10", "11. Figure 11", "12. Figure 12", "13. Figure 13", "14. Figure 14", "15. Figure 15", "16. Figure 16", "17. Figure 17", "18. Figure 18", "19. Figure 19", "20. Figure 20", "21. Figure 21", "22. Figure 22", "23. Figure 23", "24. Figure 24", "25. Figure 25", "26. Figure 26", "27. Figure 27", "28. Figure 28", "29. Figure 29", "30. Figure 30", "31. Figure 31", "32. Figure 32", "33. Figure 33", "34. Figure 34", "35. Figure 35", "36. Figure 36", "37. Figure 37", "38. Figure 38", "39. Figure 39", "40. Figure 40", "41. Figure 41", "42. Figure 42", "43. Figure 43", "44. Figure 44", "45. Figure 45", "46. Figure 46", "47. Figure 47", "48. Figure 48", "49. Figure 49", "50. Figure 50", "51. Figure 51", "52. Figure 52", "53. Figure 53", "54. Figure 54", "55. Figure 55", "56. Figure 56", "57. Figure 57", "58. Figure 58", "59. Figure 59", "60. Figure 60", "61. Figure 61", "62. Figure 62", "63. Figure 63", "64. Figure 64", "65. Figure 65", "66. Figure 66", "67. Figure 67", "68. Figure 68", "69. Figure 69", "70. Figure 70", "71. Figure 71", "72. Figure 72", "73. Figure 73", "74. Figure 74", "75. Figure 75", "76. Figure 76", "77. Figure 77", "78. Figure 78", "79. Figure 79", "80. Figure 80", "81. Figure 81", "82. Figure 82", "83. Figure 83", "84. Figure 84", "85. Figure 85", "86. Figure 86", "87. Figure 87", "88. Figure 88", "89. Figure 89", "90. Figure 90", "91. Figure 91", "92. Figure 92", "93. Figure 93", "94. Figure 94", "95. Figure 95", "96. Figure 96", "97. Figure 97", "98. Figure 98", "99. Figure 99", "100. Figure 100".

4. The fourth part of the code is the list of tables, which contains the titles and page numbers of the tables. The tables are: "1. Table 1", "2. Table 2", "3. Table 3", "4. Table 4", "5. Table 5", "6. Table 6", "7. Table 7", "8. Table 8", "9. Table 9", "10. Table 10", "11. Table 11", "12. Table 12", "13. Table 13", "14. Table 14", "15. Table 15", "16. Table 16", "17. Table 17", "18. Table 18", "19. Table 19", "20. Table 20", "21. Table 21", "22. Table 22", "23. Table 23", "24. Table 24", "25. Table 25", "26. Table 26", "27. Table 27", "28. Table 28", "29. Table 29", "30. Table 30", "31. Table 31", "32. Table 32", "33. Table 33", "34. Table 34", "35. Table 35", "36. Table 36", "37. Table 37", "38. Table 38", "39. Table 39", "40. Table 40", "41. Table 41", "42. Table 42", "43. Table 43", "44. Table 44", "45. Table 45", "46. Table 46", "47. Table 47", "48. Table 48", "49. Table 49", "50. Table 50", "51. Table 51", "52. Table 52", "53. Table 53", "54. Table 54", "55. Table 55", "56. Table 56", "57. Table 57", "58. Table 58", "59. Table 59", "60. Table 60", "61. Table 61", "62. Table 62", "63. Table 63", "64. Table 64", "65. Table 65", "66. Table 66", "67. Table 67", "68. Table 68", "69. Table 69", "70. Table 70", "71. Table 71", "72. Table 72", "73. Table 73", "74. Table 74", "75. Table 75", "76. Table 76", "77. Table 77", "78. Table 78", "79. Table 79", "80. Table 80", "81. Table 81", "82. Table 82", "83. Table 83", "84. Table 84", "85. Table 85", "86. Table 86", "87. Table 87", "88. Table 88", "89. Table 89", "90. Table 90", "91. Table 91", "92. Table 92", "93. Table 93", "94. Table 94", "95. Table 95", "96. Table 96", "97. Table 97", "98. Table 98", "99. Table 99", "100. Table 100".

5. The fifth part of the code is the list of references, which contains the titles and page numbers of the references. The references are: "1. Reference 1", "2. Reference 2", "3. Reference 3", "4. Reference 4", "5. Reference 5", "6. Reference 6", "7. Reference 7", "8. Reference 8", "9. Reference 9", "10. Reference 10", "11. Reference 11", "12. Reference 12", "13. Reference 13", "14. Reference 14", "15. Reference 15", "16. Reference 16", "17. Reference 17", "18. Reference 18", "19. Reference 19", "20. Reference 20", "21. Reference 21", "22. Reference 22", "23. Reference 23", "24. Reference 24", "25. Reference 25", "26. Reference 26", "27. Reference 27", "28. Reference 28", "29. Reference 29", "30. Reference 30", "31. Reference 31", "32. Reference 32", "33. Reference 33", "34. Reference 34", "35. Reference 35", "36. Reference 36", "37. Reference 37", "38. Reference 38", "39. Reference 39", "40. Reference 40", "41. Reference 41", "42. Reference 42", "43. Reference 43", "44. Reference 44", "45. Reference 45", "46. Reference 46", "47. Reference 47", "48. Reference 48", "49. Reference 49", "50. Reference 50", "51. Reference 51", "52. Reference 52", "53. Reference 53", "54. Reference 54", "55. Reference 55", "56. Reference 56", "57. Reference 57", "58. Reference 58", "59. Reference 59", "60. Reference 60", "61. Reference 61", "62. Reference 62", "63. Reference 63", "64. Reference 64", "65. Reference 65", "66. Reference 66", "67. Reference 67", "68. Reference 68", "69. Reference 69", "70. Reference 70", "71. Reference 71", "72. Reference 72", "73. Reference 73", "74. Reference 74", "75. Reference 75", "76. Reference 76", "77. Reference 77", "78. Reference 78", "79. Reference 79", "80. Reference 80", "81. Reference 81", "82. Reference 82", "83. Reference 83", "84. Reference 84", "85. Reference 85", "86. Reference 86", "87. Reference 87", "88. Reference 88", "89. Reference 89", "90. Reference 90", "91. Reference 91", "92. Reference 92", "93. Reference 93", "94. Reference 94", "95. Reference 95", "96. Reference 96", "97. Reference 97", "98. Reference 98", "99. Reference 99", "100. Reference 100".

6. The sixth part of the code is the list of appendices, which contains the titles and page numbers of the appendices. The appendices are: "1. Appendix 1", "2. Appendix 2", "3. Appendix 3", "4. Appendix 4", "5. Appendix 5", "6. Appendix 6", "7. Appendix 7", "8. Appendix 8", "9. Appendix 9", "10. Appendix 10", "11. Appendix 11", "12. Appendix 12", "13. Appendix 13", "14. Appendix 14", "15. Appendix 15", "16. Appendix 16", "17. Appendix 17", "18. Appendix 18", "19. Appendix 19", "20. Appendix 20", "21. Appendix 21", "22. Appendix 22", "23. Appendix 23", "24. Appendix 24", "25. Appendix 25", "26. Appendix 26", "27. Appendix 27", "28. Appendix 28", "29. Appendix 29", "30. Appendix 30", "31. Appendix 31", "32. Appendix 32", "33. Appendix 33", "34. Appendix 34", "35. Appendix 35", "36. Appendix 36", "37. Appendix 37", "38. Appendix 38", "39. Appendix 39", "40. Appendix 40", "41. Appendix 41", "42. Appendix 42", "43. Appendix 43", "44. Appendix 44", "45. Appendix 45", "46. Appendix 46", "47. Appendix 47", "48. Appendix 48", "49. Appendix 49", "50. Appendix 50", "51. Appendix 51", "52. Appendix 52", "53. Appendix 53", "54. Appendix 54", "55. Appendix 55", "56. Appendix 56", "57. Appendix 57", "58. Appendix 58", "59. Appendix 59", "60. Appendix 60", "61. Appendix 61", "62. Appendix 62", "63. Appendix 63", "64. Appendix 64", "65. Appendix 65", "66. Appendix 66", "67. Appendix 67", "68. Appendix 68", "69. Appendix 69", "70. Appendix 70", "71. Appendix 71", "72. Appendix 72", "73. Appendix 73", "74. Appendix 74", "75. Appendix 75", "76. Appendix 76", "77. Appendix 77", "78. Appendix 78", "79. Appendix 79", "80. Appendix 80", "81. Appendix 81", "82. Appendix 82", "83. Appendix 83", "84. Appendix 84", "85. Appendix 85", "86. Appendix 86", "87. Appendix 87", "88. Appendix 88", "89. Appendix 89", "90. Appendix 90", "91. Appendix 91", "92. Appendix 92", "93. Appendix 93", "94. Appendix 94", "95. Appendix 95", "96. Appendix 96", "97. Appendix 97", "98. Appendix 98", "99. Appendix 99", "100. Appendix 100".

7. The seventh part of the code is the list of index, which contains the titles and page numbers of the index. The index is: "1. Index 1", "2. Index 2", "3. Index 3", "4. Index 4", "5. Index 5", "6. Index 6", "7. Index 7", "8. Index 8", "9. Index 9", "10. Index 10", "11. Index 11", "12. Index 12", "13. Index 13", "14. Index 14", "15. Index 15", "16. Index 16", "17. Index 17", "18. Index 18", "19. Index 19", "20. Index 20", "21. Index 21", "22. Index 22", "23. Index 23", "24. Index 24", "25. Index 25", "26. Index 26", "27. Index 27", "28. Index 28", "29. Index 29", "30. Index 30", "31. Index 31", "32. Index 32", "33. Index 33", "34. Index 34", "35. Index 35", "36. Index 36", "37. Index 37", "38. Index 38", "39. Index 39", "40. Index 40", "41. Index 41", "42. Index 42", "43. Index 43", "44. Index 44", "45. Index 45", "46. Index 46", "47. Index 47", "48. Index 48", "49. Index 49", "50. Index 50", "51. Index 51", "52. Index 52", "53. Index 53", "54. Index 54", "55. Index 55", "56. Index 56", "57. Index 57", "58. Index 58", "59. Index 59", "60. Index 60", "61. Index 61", "62. Index 62", "63. Index 63", "64. Index 64", "65. Index 65", "66. Index 66", "67. Index 67", "68. Index 68", "69. Index 69", "70. Index 70", "71. Index 71", "72. Index 72", "73. Index 73", "74. Index 74", "75. Index 75", "76. Index 76", "77. Index 77", "78. Index 78", "79. Index 79", "80. Index 80", "81. Index 81", "82. Index 82", "83. Index 83", "84. Index 84", "85. Index 85", "86. Index 86", "87. Index 87", "88. Index 88", "89. Index 89", "90. Index 90", "91. Index 91", "92. Index 92", "93. Index 93", "94. Index 94", "95. Index 95", "96. Index 96", "97. Index 97", "98. Index 98", "99. Index 99", "100. Index 100".

PUBLICATION OF ANNUAL RESULTS AND ANNUAL REPORT

本公司在每年三月三十一日或之前，將本公司上一年度之財務報告及年報，刊登於香港聯合交易所有限公司之披露易網站及本公司之公司網頁，以備股東查閱。本公司亦會將該等財務報告及年報，寄給所有已登記之股東。如股東欲查閱或索取該等財務報告及年報，可致電本公司秘書處查詢。

DEFINITIONS

除非另有說明，否則本報告中使用的下列術語具有下列含義：

“**董事**”指當時獲委任為本公司董事之人士，包括主席及非執行董事。
 “**股東**”指本公司之股東，包括任何登記為股東之人士。

“**公司**”指本公司，即奧鴻藥業有限公司。
 “**董事會**”指本公司之董事會。
 “**秘書**”指本公司之秘書。

“**控股股東**”指當時擁有或控制本公司之股份，足以對本公司之業務及財務政策產生重大影響之人士。

“**主要股東**”指當時擁有或控制本公司之股份，足以對本公司之業務及財務政策產生重大影響之人士，其身份由本公司之董事會決定。

“**董事會主席**”指當時獲委任為本公司董事會主席之人士。

“**董事會副主席**”指當時獲委任為本公司董事會副主席之人士。

“**董事會秘書**”指當時獲委任為本公司董事會秘書之人士。

“**董事會成員**”指當時獲委任為本公司董事會成員之人士。

“**董事會成員之薪酬**”指本公司董事會成員之薪酬，包括薪金、獎金及福利。

“**董事會成員之委任**”指本公司董事會成員之委任，包括委任、續任及辭職。
 本公司之董事會成員，由錦州奧鴻藥業有限公司之股東委任。

“**董事會成員之任期**”指本公司董事會成員之任期，由本公司之股東決定。

“[H]”

[illegible]

“*And I will*”

[illegible]

“▲”] ”

[illegible]

“▲”

▲ **1999**

“ ”

[illegible]

“ ”

$$\begin{aligned} & \left[\begin{array}{c} \mathbf{P} \\ \mathbf{Q} \end{array} \right]_{I+1} = \left[\begin{array}{c} \mathbf{P} \\ \mathbf{Q} \end{array} \right]_I + \left[\begin{array}{c} \mathbf{P} \\ \mathbf{Q} \end{array} \right]_{I+1} - \left[\begin{array}{c} \mathbf{P} \\ \mathbf{Q} \end{array} \right]_I \\ & \left[\begin{array}{c} \mathbf{P} \\ \mathbf{Q} \end{array} \right]_{I+1} = \left[\begin{array}{c} \mathbf{P} \\ \mathbf{Q} \end{array} \right]_I + \left[\begin{array}{c} \mathbf{P} \\ \mathbf{Q} \end{array} \right]_{I+1} - \left[\begin{array}{c} \mathbf{P} \\ \mathbf{Q} \end{array} \right]_I \end{aligned}$$

“ ”

[illegible]

“] ”

利北京國 易有 公司/上 美中互

“ ”

$$- \frac{1}{\sqrt{\pi}} \int_{-\infty}^{\infty} \frac{f(t)}{(t-x)^2} dt = f'(x) - \frac{1}{\sqrt{\pi}} \int_{-\infty}^{\infty} \frac{f(t)}{(t-x)^3} dt$$

“ ”

$$- \frac{1}{\sqrt{\pi}} \int_{-\infty}^{\infty} \frac{e^{-t^2}}{t} dt = 0$$

“ h_1, h_2, h_3 ”

[illegible]

“ 1, 1 ”

上海復星醫藥集團股份有限公司

"But, but...!! But..."

[illegible]

“ ”

-] L] , 中國證券監督管理委員會,

“ ”

$$\frac{1}{\sqrt{2}} \begin{bmatrix} 1 & 1 \\ 1 & -1 \end{bmatrix} = \frac{1}{\sqrt{2}} \begin{bmatrix} 1 & 0 \\ 0 & 1 \end{bmatrix}$$


“ R ”

— **1991** *Journal of the American Medical Association* 266: 1033-1036

“ ”

1. \mathcal{L}_1 and \mathcal{L}_2

“↑”



“ $\begin{bmatrix} 1 & 1 \\ 1 & 1 \end{bmatrix} \in \mathbb{R}^{2 \times 2}$, $\begin{bmatrix} 1 & 1 \\ 1 & 1 \end{bmatrix} \in \mathbb{R}^{2 \times 2}$ ”

公司 / 佛山復星禪誠醫 有

[illegible]

[illegible]

“ 叮、叮 ”

國藥控股股份有限公司

“ 11 11 11 ”

國藥產業投 有 公司

“] ”

[illegible]

“ ”

$$\frac{1}{100} \times 100 = 1 \quad \text{and} \quad \frac{1}{1000} \times 1000 = 1$$

“ I b]_] ”

$$I \vdash \frac{[A]_{\perp} \vdash I \quad \perp \vdash A}{A}_{\perp}, \quad I \vdash A \vdash [A]_{\perp} \quad I \vdash A \vdash [A]_{\perp} \quad I \vdash A \vdash [A]_{\perp}$$

" "H" "I"] "

[illegible]

“ ”

1. \mathcal{H}^1 is a separable Banach space.

“

$\frac{1}{2} \times \frac{1}{2} = \frac{1}{4}$

$\left[\begin{array}{c} \text{---} \\ \text{---} \\ \text{---} \end{array} \right]_I \left[\begin{array}{c} \text{---} \\ \text{---} \\ \text{---} \end{array} \right]_I \left[\begin{array}{c} \text{---} \\ \text{---} \\ \text{---} \end{array} \right]_I \left[\begin{array}{c} \text{---} \\ \text{---} \\ \text{---} \end{array} \right]_I$

化醫藥集團有限公司 江蘇萬邦生

“ ”

$\nabla \cdot \mathbf{h} = 0$
 $\nabla \cdot \mathbf{u} = 0$
 $\nabla \cdot \mathbf{v} = 0$
 $\nabla \cdot \mathbf{w} = 0$

“ R ”

$$\nabla \cdot \mathbf{F} = \frac{1}{r} \frac{\partial}{\partial r} (r F_r) + \frac{1}{r \sin \theta} \frac{\partial}{\partial \theta} (\sin \theta F_\theta) + \frac{1}{r \sin \theta} \frac{\partial}{\partial \phi} (F_\phi \sin \theta)$$

“ b ”

海復星醫藥集團股份有限公司董事／有關人員進行證券交易的書面守則》。

“ 11 11 11 ”

星諾醫藥科技有 限公司 江蘇

“ 1. 2. 3. 4. 5. ”

廣州市心怡堂大藥房有限公司

"...the ..."

連鎖有限公司 徐州萬邦藥房

“ ”

星晨婦兒醫 有 限 公 司 徐 州

“ ▲ ”

[illegible]

“ ”

1400

Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*
Wu Yifang
C 1/2

[illegible]

A $\frac{K}{r}$ $\frac{K}{r}$ $C^{\frac{K}{r}}$ r $Mr. W$ $\frac{K}{r}$ $Mr. W$ K $Mr. G$ $Mr. W$ D ; - K r $\frac{K}{r}$ $C^{\frac{K}{r}}$ r $Mr. C$ Q $Mr. \frac{K}{r}$ F $Mr. Mr. P$ D ; - K r $\frac{K}{r}$ $C^{\frac{K}{r}}$ r $M. L$ L $Mr. T$ G $Mr. W$ Q $Mr. \frac{K}{r}$ T S H .

$$F_r \quad K \quad r$$